BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining ...

To choose the best lead candidates during drug and antibody screening, scientists characterize a molecule’s binding properties, such as kinetics and affinity. Robust assay design reduces experimental ...

Drug discovery is a complex field that demands rigorous testing and comprehensive data analysis to ensure potential drug candidates can advance to clinical trials. One critical step is screening for ...

Determining and evaluating the affinity of small molecule binding to a therapeutic target is a major component of drug discovery and lead optimization. In a technical note entitled “Label-free ...

Cell-surface proteins are critical therapeutic targets and are vital to cellular communication, signaling, and homeostasis.

Bidirectional vesicle transport along microtubules is necessary for cell viability and function, particularly in neurons. When multiple motors are attached to a vesicle, the distance a vesicle travels ...

Surface plasmon resonance (SPR) has revolutionized the study of the intricate protein interactions that are required for the execution and maintenance of complex biological processes, enabling the ...

How can treating neurological disease overcome challenges like the synthesis of small molecule agents that penetrate the blood-brain barrier, in order to sustain target engagement at low drug ...

Researchers at ESPCI Paris and Quantum-Si (QSI) demonstrate scalable platform for parallel binding kinetics and sequencing in new preprint The process works by tagging protein variants, such as ...

A research team led by Prof. TAN Weihong and Prof. WU Qin from the Hangzhou Institute of Medicine (HIM) of the Chinese Academy of Sciences has developed a pioneering, multi-modal platform called SPARK ...